Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors
DEREK MUNRO: Like it would look like you couldnt even do what youre trying to teach
This stuff isnt snake oil
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Under current guidelines, the Medicines and Healthcare products Regulatory Agency (MHRA), who are responsible for regulating all medicines and medical devices in the UK by ensuring they work as expected and are acceptably safe, told Women's Health
Preparing to inject semaglutide involves a few key steps that help ensure youre administering the correct dosage form and following the appropriate injection schedule